小肾癌主动监测患者的条件生存分析
本研究基于前瞻性主动监测(AS)方案,纳入272例≤4 cm小肾癌(SRM)患者,评估条件生存与肿瘤生长。结果显示,<3 cm肿瘤患者若已存活2年,后续5年生存概率为0.84–0.85;存活3年后升至0.91。AS与部分肾切除术(PN)的总生存约7年内相似,之后PN显示死亡风险降低趋势(HR 0.57;P=0.07)。
要点
- <3 cm SRM患者AS 2年后5年生存概率为0.84–0.85,3年后升至0.91。
- AS与PN总生存约7年内相似,之后PN有死亡风险降低趋势(HR 0.57;P=0.07)。
- 肿瘤<3 cm时生长缓慢(β=0.12;P<0.001),生长速率平行。
核心结论
- SRM<3 cm患者AS的条件生存概率在2年后提高。
- 该信息有助于泌尿外科医生和患者在AS 2年后决定继续AS还是干预。
研究设计与样本
- 前瞻性AS方案,2005年5月至2016年1月单中心入组。
- 纳入≤4 cm SRM且有系列横断面影像可供院内回顾的患者,共272例。
- 采用Kaplan-Meier法估计总生存(OS),Cox比例风险模型建模。
- 使用界标分析评估初始扫描后2年以上的生存结局。
- 采用逆概率治疗加权比较AS与部分肾切除术(PN)的相对条件生存。
主要发现
- 平均初始SRM大小为1.74±0.77 cm,最接近2年界标时的平均大小为1.97±0.83 cm。
- AS 2年后,<3 cm肿瘤患者存活至5年的概率为0.84–0.85;存活3年后升至0.91。
- 肿瘤<3 cm时生长缓慢(β:0.12;P<0.001),生长速率平行。
- AS与PN的总生存约7年内相似,之后PN显示死亡风险降低趋势(HR 0.57;P=0.07)。
临床怎么用
- 对于<3 cm SRM患者,AS 2年后可依据条件生存概率(0.84–0.85)与患者讨论继续AS或干预。
- AS 3年后生存概率升至0.91,可进一步支持继续AS的决策。
- AS与PN约7年内总生存相似,长期(>7年)PN可能有死亡风险降低趋势,需个体化权衡。
局限性
- 单中心前瞻性队列,样本量272例。
- PN与AS的比较为观察性设计,采用逆概率治疗加权,可能存在残余混杂。
- PN死亡风险降低趋势未达统计学显著性(P=0.07)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine conditional survival for patients with small renal masses (SRMs) undergoing active surveillance (AS). MATERIALS AND METHODS: Patients were enrolled in a prospective AS protocol at our institution between May 2005 and January 2016. Patients with SRMs ≤4 cm with serial cross-sectional imaging available in-house for review were included. Overall survival (OS) was estimated using the Kaplan-Meier method and modelled via Cox proportional hazards models. The primary endpoints analysed were the conditional probability of survival and tumour growth over time. Landmark analysis was used to evaluate survival outcomes beyond the 2-year mark after the initial scan. The relative conditional survival of patients on AS was compared to those undergoing partial nephrectomy (PN) using inverse probability of treatment weighting. RESULTS: A total of 272 patients were included in this analysis. The mean initial SRM size was 1.74 ± 0.77 cm, and the mean mass size closest to the 2-year mark was 1.97 ± 0.83 cm. The likelihood of continued survival to 5 years improved after the 2-year landmark. Patients with masses <3 cm who survived the first 2 years on AS had a 0.84-0.85 chance of surviving to 5 years, and if they survived 3 years, the probability of surviving to 5 years improved to 0.91. A slow tumour growth (β: 0.12; P < 0.001) with parallel growth rates was found for tumours <3 cm. Patients on AS and those who underwent PN had similar OS for ~7 years, beyond which PN demonstrated a trend of lower risk of death compared with AS (hazard ratio 0.57; P = 0.07). CONCLUSIONS: The conditional survival probability of patients with SRMs <3 cm on AS increased after 2 years. This information may prove useful to urologists and patients who are considering continuing AS vs intervention after the first 2 years on AS.
引用
- Petros FG, Venkatesan AM, Kaya D, et al. Conditional survival of patients with small renal masses undergoing active surveillance. BJU Int. 2018. PMID: 30007044. doi:10.1111/bju.14486
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。